US NIH launches $215m Partnership for Accelerating Cancer Therapies

The US National Institutes of Health (NIH), along with 11 biopharmaceutical companies, has launched a $215m five-year public-private research collaboration to advance new cancer immunotherapy strategies for more patients.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Abstract The field of cancer immunology stepped into the limelight this year when James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation. Among many exciting advances contributing to the coming of age of tumour immunology as a viable clinical specialty has been the ability to progress from the initial elucidation of tumour antigens, such as the melanoma antigen, MAGE-1, to high-throughput sequencing facilitating identification of T cell epitopes from diverse tumour neoantigens. This has resulted from the...
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
Authors: Schanz M, Schricker S, Pfister F, Alscher MD, Kimmel M Abstract Cancer patients often exhibit preexisting renal impairment and are simultaneously at risk for developing further kidney injury due to direct or indirect complications of oncological therapies. The nature of kidney injury is highly dependent on the therapy regimen used, and the spectrum of possible kidney stressors has widened as a result of the development of new therapeutic modalities such as molecular therapy or immunotherapy. Indirect renal complications are often due to volume depletion or other therapy-related side effects. Direct toxicit...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
The 2018 Nobel Prize in physiology or medicine recognizes James P. Allison and Tasuku Honjo for “their discovery of cancer therapy by inhibition of negative immune regulation.” This is a developing story. It will be updated.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
Clinical progress in cancer immunotherapy has been slow; however, within the last 5  years, breakthrough successes have brought immunotherapy to the forefront in cancer therapy. Promising results have been observed in solid tumors and hematologic malignancies. Most treatment modalities have shown limited efficacy as monotherapy. The complex nature of cancer and the immunosuppressi ve microenvironment emphasizes the need to personalize immunotherapy by manipulating the patient’s own immune system. For successful and long-lasting cure of cancer, a multimodal approach is essential, combining antitumor cell therapy ...
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: These results support the clinical use of consensus MAGE-A immunogens with the capacity to target multiple MAGE-A family members to prevent tumor immune escape. PMID: 30262507 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractIn recent years, immune cells were shown to play critical roles in tumor growth and metastatic progression. In this context, neutrophils were shown to possess both pro- and anti-tumor properties. To exert their anti-tumor effect, neutrophils need to migrate towards, and form physical contact with tumor cells. Neutrophils secrete H2O2 in a contact-dependent mechanism, thereby inducing a lethal Ca2+ influx via the activation of the H2O2-dependent TRPM2 Ca2+ channel. Here, we explored the mechanism regulating neutrophil chemoattraction to tumor cells. Interestingly, we found that TRPM2 plays a role in this context as ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
This article reviews mechanism and therapeutic application of CRISPR/Cas9 technology, accuracy of this technology, cancer immunotherapy by CAR T cells, the application of CRISPR technology for the production of universal CAR T cells, improving their antitumor efficacy, and biotech companies that invested in CRISPR technology for CAR-T cell therapy. PMID: 30261221 [PubMed - as supplied by publisher]
Source: Human Immunology - Category: Allergy & Immunology Authors: Tags: Hum Immunol Source Type: research
AbstractIn recent years, immune cells were shown to play critical roles in tumor growth and metastatic progression. In this context, neutrophils were shown to possess both pro- and anti-tumor properties. To exert their anti-tumor effect, neutrophils need to migrate towards, and form physical contact with tumor cells. Neutrophils secrete H2O2 in a contact-dependent mechanism, thereby inducing a lethal Ca2+ influx via the activation of the H2O2-dependent TRPM2 Ca2+ channel. Here, we explored the mechanism regulating neutrophil chemoattraction to tumor cells. Interestingly, we found that TRPM2 plays a role in this context as ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
UCLA researchers have discovered  genetic similarities between the adult stem cells responsible for maintaining and repairing epithelial tissues — which line all of the organs and cavities inside the body — and the cells that drive aggressive epithelial cancers. Their findings could bring about a better understanding of how ag gressive, treatment-resistant cancers develop and progress, and could eventually lead to new drugs for a range of advanced epithelial cancers such as lung, prostate and bladder cancers. The study, led by senior authors Owen Witte and Thomas Graeber, both of the  UCLA E...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Immunotherapy | National Institutes of Health (NIH) | Partnerships | Pharmaceuticals